Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 534 clinical trials
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Background The drug IL-15 activates the immune system. The drugs nivolumab and ipilimumab unblock immune cells. The drugs together may allow immune cells to recognize and attack cancer cells, causing tumors to shrink. Objective To test the effects and maximum dose of IL-15, nivolumab, and ipilimumab. Eligibility People ages 18 …

  • 0 views
  • 16 May, 2022
  • 1 location
Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17) (BORTEM-17)

This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.

blood transfusion
karnofsky performance status
corticosteroids
platelet count
recurrent glioblastoma
  • 48 views
  • 13 Feb, 2022
  • 2 locations
Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer

This is an open-label, exploratory study to evaluate nivolumab with or without ipilimumab based on percentage of tumoral CD8 cells at the time of treatment in participants with varying advanced solid tumors. Participants who have a tumor with ≥ 15% CD8 cells (classified as CD8 high) will receive nivolumab monotherapy, …

  • 6 views
  • 13 Apr, 2022
  • 3 locations
Disulfiram and Cisplatin in Refractory TGCTs. (DISGCT)

Non-randomized, open-label, single center trial to assess efficacy (as measured by overall response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple relapsed/refractory germ cell tumors (GCTs).

cancer chemotherapy
high dose chemotherapy
measurable disease
gonadotropin
seminoma
  • 15 views
  • 08 Feb, 2022
  • 1 location
MRD-guided Treatment in NPM1mut AML Patients (PEMAZA)

Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable residual disease (MRD).

remission
residual tumor
cell transplantation
cytarabine
azacitidine
  • 2 views
  • 16 Feb, 2022
  • 11 locations
Study to Nivolumab Following Preoperative Chemoradiotherapy

This is a phase Ib/II, open-label, single-arm, multicenter study to investigate the safety, efficacy, and proof of concept (POC) of monotherapy with nivolumab, an anti-PD-1 antibody drug, as a sequential therapy following chemoradiotherapy (CRT) with capecitabine and subsequent surgical therapy in patients with locally advanced resectable rectal cancer.

rectal surgery
capecitabine
metastasis
abdominoperineal resection
adenocarcinoma
  • 16 views
  • 27 Jan, 2022
  • 3 locations
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or nivolumab+ipilimumab immunotherapy in patients with selected advanced solid tumors. The Phase II portion will …

measurable disease
carcinoma
tubal ligation
serum bilirubin
nivolumab
  • 14 views
  • 25 Mar, 2022
  • 1 location
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts. Part A is a 3+3 dose escalation to define the recommended RP2D; this part will include metastatic melanoma, platinum resistant ovarian cancer, and pancreatic cancer …

  • 1 views
  • 15 Mar, 2021
  • 3 locations
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with …

  • 6 views
  • 22 Apr, 2022
  • 5 locations
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

The purpose of the study is to test the efficacy and tolerability of a combination treatment of methotrexate, ibrutinib, and temozolomide (MIT regimen) in treating patients who have newly-diagnosed primary CNS lymphoma.

methotrexate
leucovorin
neutrophil count
  • 0 views
  • 19 Apr, 2022
  • 2 locations